Stock Round UP (3) SanBio SanBio, a regenerative medicine company, has been making headlines recently. The company is focused on developing treatments for neurological disorders using stem cell technology. Their lead product, SB623, is currently in clinical trials for conditions such as stroke and traumatic brain injury. Investors are closely watching the progress of these trials, as positive results could significantly boost the company's stock price. Additionally, SanBio has strategic partnerships with major pharmaceutical companies, which adds to its credibility and potential for future growth. The market is optimistic about the company's innovative approach and its potential to revolutionize treatment options for severe neurological conditions.